Aug 12 2015
Dynatronics Corporation (NASDAQ: DYNT) today announced its patent for "Systems and Methods for Providing a Thermo-electro-stimulation Probe Device" (US Patent No. 9,084,665) has been granted by the U.S. Patent and Trademark Office. This technology is incorporated in the company's ThermoStim Probe used in the delivery of therapeutic treatments.
The innovative ThermoStim Probe delivers thermal (hot and cold) therapy and/or electrotherapy in a targeted, attended treatment. Over the past year, this novel technology has become popular among physical therapists, sports medicine practitioners and athletic trainers for increasing local blood circulation, reducing muscle spasm and relieving pain in patients and athletes.
"The unique advantages of the ThermoStim Probe, which include reduced treatment time with the simultaneous delivery of three distinct treatments and greater ease of use compared to conventional methods, should make this important new tool a 'must have' for clinicians," said Larry K. Beardall, Executive Vice President of Sales and Marketing. "Gaining a patent on this new technology distances us from competitors and will provide us a proprietary advantage for many years to come."
"Because the probe is operated from the control console of the SolarisPlus units, demand for SolarisPlus units has risen commensurate with the demand for the ThermoStim Probe," added Beardall.
"We believe the unique advantages of the ThermoStim Probe, together with the expansion of our distribution channels both domestically and internationally, will help drive sales of our therapeutic device products going forward," he concluded.
SOURCE Dynatronics Corporation
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare